Ghadeer K Dawwas

List of Publications by Citations

Source: https://exaly.com/author-pdf/6215510/ghadeer-k-dawwas-publications-by-citations.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23 150 7 12 g-index

27 238 6.5 3.61 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
23	Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. <i>Lancet Haematology,the</i> , 2019 , 6, e20-e28	14.6	43
22	Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 28-36	6.7	38
21	Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists. <i>Cardiovascular Diabetology</i> , 2018 , 17, 102	8.7	14
20	The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety. <i>Cardiovascular Diabetology</i> , 2020 , 19, 25	8.7	10
19	Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism. <i>American Journal of Health-System Pharmacy</i> , 2020 , 77, 188-195	2.2	8
18	Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation: A Population-Based Cohort Study. <i>Annals of Internal Medicine</i> , 2021 , 174, 910-919	8	8
17	Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data. <i>Annals of Internal Medicine</i> , 2021 ,	8	7
16	Comparative Effectiveness and Safety of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome: A Retrospective Cohort Analysis. <i>Pharmacotherapy</i> , 2019 , 39, 912-920	5.8	6
15	Screening to identify signals of opioid drug interactions leading to unintentional traumatic injury. <i>Biomedicine and Pharmacotherapy</i> , 2020 , 130, 110531	7.5	6
14	Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 705-710	6.7	3
13	Risk of sudden cardiac arrest and ventricular arrhythmia with sulfonylureas: An experience with conceptual replication in two independent populations. <i>Scientific Reports</i> , 2020 , 10, 10070	4.9	2
12	Population-Based Signals of Antidepressant Drug Interactions Associated With Unintentional Traumatic Injury. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 409-423	6.1	2
11	Apixaban has Superior Effectiveness and Safety Compared to Rivaroxaban in Patients with Commercial Healthcare Coverage: A Population-Based Analysis in Response to CVS 2022 Formulary Changes <i>American Journal of Hematology</i> , 2022 ,	7.1	1
10	Prevalence and Factors Associated With Fecal Urgency Among Patients With Ulcerative Colitis and Crohn® Disease in the Study of a Prospective Adult Research Cohort With Inflammatory Bowel Disease. <i>Crohn</i> s & Colitis 360, 2021 , 3,	1.4	1
9	Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2021 , 174, 1490	8	O
8	Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis. <i>Clinical Therapeutics</i> , 2020 , 42, e161-e176	3.5	0
7	Signals of Muscle Relaxant Drug Interactions Associated with Unintentional Traumatic Injury: A Population-Based Screening Study <i>CNS Drugs</i> , 2022 , 36, 389	6.7	O

LIST OF PUBLICATIONS

6	Outcomes of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease <i>Current Cardiology Reports</i> , 2022 , 1	4.2	O
5	Can apixaban prevent venous thromboembolism better than rivaroxaban? - Authors' reply. <i>Lancet Haematology,the</i> , 2019 , 6, e181-e182	14.6	
4	Compared to commercially insured patients, Medicare advantage patients adopt newer diabetes drugs more slowly and adhere to them less. <i>Endocrinology, Diabetes and Metabolism</i> , 2021 , 4, e00245	2.7	
3	The Impact of Introducing Patient-Reported Inflammatory Bowel Disease Symptoms via Electronic Survey on Clinic Visit Length, Patient and Provider Satisfaction, and the Environment Microbiome. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 746-750	4.5	
2	Comments on the article "Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study". <i>Arthritis Research and Therapy</i> , 2018 , 20, 198	5.7	
1	Cardiovascular and major bleeding outcomes with antiplatelet and direct oral anticoagulants in patients with acute coronary syndrome and atrial fibrillation: A population-based analysis. <i>American Heart Journal</i> , 2021 , 242, 71-81	4.9	